HIV – Medxy AI

Accelerated Epigenetic Aging in HIV: Insights from a Systematic Review

By MedXY 10/22/2025

Systematic review evidence supports accelerated epigenetic aging in people living with HIV compared to uninfected individuals, highlighting the need for further research considering antiretroviral therapy and confounding factors.

HIV/AIDS Infectious Diseases Specialties

Long-Term Health Risks in HIV Patients with Immune Non-Response Despite Antiretroviral Therapy

By MedXY 10/22/2025

Immune non-response despite ART in people with HIV significantly increases risk of both AIDS-defining and non-AIDS-defining comorbidities, underscoring the need for enhanced risk assessment beyond CD4+ T-cell counts.

Dermatology HIV/AIDS Specialties

Evolving Dermatologic Landscape in HIV: Prevalence, Incidence, and Risk Factors in the Modern ART Era from the DC Cohort

By MedXY 10/22/2025

Despite advances in antiretroviral therapy, dermatologic diseases remain prevalent in people with HIV, with incidence declining yet significant disparities persisting related to immune status, demographics, and structural factors.

HIV/AIDS Infectious Diseases Specialties

Understanding Motivations and Barriers in Donation-Based HIV/STI Interventions: Insights from a Systematic Review

By MedXY 10/22/2025

This review synthesizes motivations, facilitators, and barriers of donation-based interventions in HIV/STI research, revealing key factors that enhance access to services through prosocial behaviors in diverse global settings.

HIV/AIDS Infectious Diseases Public Health Specialties

HIV Among Older Adults in Sub-Saharan Africa: Epidemiology, Risks, and Treatment Insights from the AWI-Gen Longitudinal Study

By MedXY 10/20/2025

This multicentre longitudinal cohort study reveals significant HIV prevalence and incidence among adults aged 40 and older in sub-Saharan Africa, highlighting age, gender, education, and rural residency as critical factors influencing HIV risk and treatment outcomes.

Cardiology HIV/AIDS news Specialties

Early HIV Treatment and Cardiovascular Health: Insights from the START Study

By MedXY 10/09/2025

Early ART initiation in HIV-positive adults with high CD4+ counts shows no overall cardiovascular benefit, but reduced CVD events in women suggest potential sex-specific effects needing further study.

HIV/AIDS news Specialties

Efficacy of Bictegravir-Based Regimen vs. Ritonavir-Boosted Protease Inhibitors in HIV Patients on Second-Line Therapy in Haiti: Insights from a Randomized Non-Inferiority Trial

By MedXY 09/21/2025

A randomized trial in Haiti demonstrates that switching to bictegravir, emtricitabine, and tenofovir alafenamide is non-inferior to ritonavir-boosted protease inhibitors in maintaining viral suppression among second-line HIV therapy patients.

HIV/AIDS news Nursing & care Pediatrics Specialties

Bridging Pediatric and Adult HIV Care: Evaluating Outcomes and Perspectives from a Novel Transition Clinic for Young People Living with HIV

By MedXY 08/16/2025

This mixed-methods study assesses a novel Adolescent and Young Adult Healthcare Transition (AYA HCT) clinic that achieved high retention but suboptimal viral suppression among youth with HIV, highlighting key strengths and barriers.

Clinical Updates HIV/AIDS Infectious Diseases news Specialties

M72/AS01E-4 Tuberculosis Vaccine: Promising Advances for HIV-Positive Populations in High-Burden Settings

By MedXY 08/05/2025

A phase 2 trial in South Africa shows that the M72/AS01E-4 TB vaccine is safe and immunogenic for virally suppressed, ART-treated HIV-positive adolescents and adults, supporting its potential to address a key unmet clinical need.

Clinical Updates Infectious Diseases Public Health Specialties

Real-World Safety and Effectiveness of MVA-BN Vaccination Against Mpox: Evidence from German, Systematic Review, and Immunogenicity Cohorts

By MedXY 08/03/2025

MVA-BN vaccination is safe and effective against mpox in at-risk populations, but reduced protection is noted in people living with HIV. Dose strategies and patient immunological status may affect outcomes.

Clinical Updates HIV/AIDS news Specialties

Comparative Effectiveness of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide for Maintenance Therapy in HIV: Insights from the PASO-DOBLE Trial

By MedXY 08/03/2025

The PASO-DOBLE trial demonstrated non-inferiority of dolutegravir/lamivudine versus bictegravir/FTC/TAF for maintenance in virologically suppressed HIV-1 adults, with similar efficacy and safety over 48 weeks.

Clinical Updates HIV/AIDS news Specialties

Advances in Second-Line Antiretroviral Therapy for Children with HIV in Africa: Insights from the CHAPAS-4 Trial

By MedXY 08/02/2025

TAF–emtricitabine and dolutegravir-based regimens outperform standard options as second-line ART for African children with HIV, offering improved viral suppression and safety.

Clinical Updates HIV/AIDS news Specialties

Novel HIV Peptides Identified During Treatment Interruption May Inform Next-Generation Therapeutic Strategies

By MedXY 07/30/2025

Discovery of genetically conserved, mutation-intolerant HIV peptides in rebound virus during analytic treatment interruption highlights new avenues for mRNA vaccine development and functional HIV cure strategies.

HIV/AIDS news Specialties

Assessing Antibiotic Use During Pregnancy: Impact on Birth Outcomes in HIV Contexts

By MedXY 07/29/2025

A clinical study reveals that trimethoprim-sulfamethoxazole does not significantly improve infant birth weight or related outcomes in HIV-positive pregnancies.